Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed has gained useful data from a phase I clinical trial to evaluate the delivery and absorption of a compound currently used to treat gastroesophageal reflux disease, or GERD.
Subscribe to our email newsletter
The phase I clinical trial was conducted in healthy volunteers to evaluate specific pharmacokinetic and absorption behavior of the drug compound once it is in the gastrointestinal tract.
The results demonstrated both an absorption and bioavailability profile, which provided clear criteria to design Depomed’s controlled release formulation of the drug to potentially facilitate improved therapy.
GERD is common, with an estimated lifetime prevalence of 25% to 35% in the US population. Depomed is exploring the possibility of developing an oral, controlled release GERD therapy that may specifically address nocturnal acid breakthrough.
“This is an exciting new program which we believe is ready to advance into later stage clinical development,” said Dr Bret Berner, chief scientific officer of Depomed. “We believe that our drug delivery approach for this compound may specifically address nocturnal acid breakthrough, a condition which current agents do not adequately address.”